Evidence mapPaperPMID 36587202Full record

ArticleCardiovascular diabetology2022

High-density lipoprotein subclasses and cardiovascular disease and mortality in type 2 diabetes: analysis from the Hong Kong Diabetes Biobank.

Qiao Jin, Eric S H Lau, Andrea O Luk, Claudia H T Tam, Risa Ozaki, Cadmon K P Lim, Hongjiang Wu, Elaine Y K Chow, Alice P S Kong, Heung Man Lee and 30 more

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 15 institutions in 3 countries.

Qiao JinDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Eric S H LauDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Andrea O LukDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Claudia H T TamDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Risa OzakiDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Cadmon K P LimDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Hongjiang WuDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Elaine Y K ChowDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Alice P S KongDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Heung Man LeeDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Baoqi FanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Alex C W NgDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Guozhi JiangSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Ka Fai LeeDepartment of Medicine and Geriatrics, Kwong Wah Hospital, Yau Ma Tei, Hong Kong Special Administrative Region, China.
Shing Chung SiuDiabetes Centre, Tung Wah Eastern Hospital, Sheung Wan, Hong Kong Special Administrative Region, China.
Grace HuiDiabetes Centre, Tung Wah Eastern Hospital, Sheung Wan, Hong Kong Special Administrative Region, China.
Chiu Chi TsangDiabetes and Education Centre, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong Special Administrative Region, China.
Kam Piu LauNorth District Hospital, Sheung Shui, Hong Kong Special Administrative Region, China.
Jenny Y LeungDepartment of Medicine and Geriatrics, Ruttonjee Hospital, Wan Chai, Hong Kong Special Administrative Region, China.
Man-Wo TsangDepartment of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong Special Administrative Region, China.
Elaine Y N CheungDepartment of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong Special Administrative Region, China.
Grace KamDepartment of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong Special Administrative Region, China.
Ip Tim LauTseung Kwan O Hospital, Hang Hau, Hong Kong Special Administrative Region, China.
June K LiDepartment of Medicine, Yan Chai Hospital, Tsuen Wan, Hong Kong Special Administrative Region, China.
Vincent T YeungCentre for Diabetes Education and Management, Our Lady of Maryknoll Hospital, Wong Tai Sin, Hong Kong Special Administrative Region, China.
Emmy LauDepartment of Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong Special Administrative Region, China.
Stanley LoDepartment of Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong Special Administrative Region, China.
Samuel FungDepartment of Medicine and Geriatrics, Princess Margaret Hospital, Lai Chi Kok, Hong Kong Special Administrative Region, China.
Yuk Lun ChengDepartment of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong Special Administrative Region, China.
Chun Chung ChowDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Weichuan YuDepartment of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Kowloon, Hong Kong Special Administrative Region, China.
Stephen K W TsuiSchool of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Yu HuangSchool of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Hui-Yao LanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Cheuk Chun SzetoDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Wing Yee SoDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Alicia J JenkinsDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Juliana C N ChanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
Ronald C W MaDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China. rcwma@cuhk.edu.hk.
Hong Kong Diabetes Biobank Study Group
Chinese University of Hong Kong · CNPrince of Wales Hospital · CNUnited Christian Hospital · CNAlice Ho Miu Ling Nethersole Hospital · CNDepartment of Health · CNTung Wah Eastern Hospital · CNCity University of Hong Kong · HKKwong Wah Hospital · CNOur Lady of Maryknoll Hospital · CNPamela Youde Nethersole Eastern Hospital · CNRuttonjee Hospital · CNSun Yat-sen University · CNTseung Kwan O Hospital · CNUniversity of Hong Kong · HKUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHigh-density lipoproteins (HDL) comprise particles of different size, density and composition and their vasoprotective functions may differ. Diabetes modifies the composition and function of HDL. We assessed associations of HDL size-based subclasses with incident cardiovascular disease (CVD) and mortality and their prognostic utility. RESEARCH DESIGN AND

methodsHDL subclasses by nuclear magnetic resonance spectroscopy were determined in sera from 1991 fasted adults with type 2 diabetes (T2D) consecutively recruited from March 2014 to February 2015 in Hong Kong. HDL was divided into small, medium, large and very large subclasses. Associations (per SD increment) with outcomes were evaluated using multivariate Cox proportional hazards models. C-statistic, integrated discrimination index (IDI), and categorial and continuous net reclassification improvement (NRI) were used to assess predictive value.

resultsOver median (IQR) 5.2 (5.0-5.4) years, 125 participants developed incident CVD and 90 participants died. Small HDL particles (HDL-P) were inversely associated with incident CVD [hazard ratio (HR) 0.65 (95% CI 0.52, 0.81)] and all-cause mortality [0.47 (0.38, 0.59)] (false discovery rate < 0.05). Very large HDL-P were positively associated with all-cause mortality [1.75 (1.19, 2.58)]. Small HDL-P improved prediction of mortality [C-statistic 0.034 (0.013, 0.055), IDI 0.052 (0.014, 0.103), categorical NRI 0.156 (0.006, 0.252), and continuous NRI 0.571 (0.246, 0.851)] and CVD [IDI 0.017 (0.003, 0.038) and continuous NRI 0.282 (0.088, 0.486)] over the RECODe model.

conclusionSmall HDL-P were inversely associated with incident CVD and all-cause mortality and improved risk stratification for adverse outcomes in people with T2D. HDL-P may be used as markers for residual risk in people with T2D.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2AdultBiological Specimen BanksCholesterol, HDLHong KongHumansLipoproteins, HDLRisk FactorsCholesterol, HDLLipoproteins, HDLCardiovascular diseaseHigh-density lipoprotein particlesHigh-density lipoprotein subclassesMortalityPrognostic markerResidual riskRisk stratificationType 2 diabetes

Identifiers

PMID36587202
PMCPMC9805680
OpenAlexW4313395888

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.